Oligonucleotide– tag –
-
siRNA Overcomes Gene Silencing Challenges with LNP and GalNAc Conjugation, Expanding Therapeutic Applications
Inside Therapeutics USA Overview Inside Therapeutics details how siRNA, while offering transformative gene silencing, is overcoming delivery challenges through lipid nanoparticles (LNP) and N-acetylgalactosamine (GalNAc) conjugation tech... -
Investor Focus: RNA Platform Success Hinges on Extrahepatic Delivery Capabilities Beyond the Liver
Bioprocess Online USA Overview Bioprocess Online highlights that a key question for investors evaluating RNA therapeutic platforms is the ability to effectively deliver RNA to diverse extrahepatic organs. While current successes often le... -
Patient-Specific Lymphoid Organ Chips Recapitulate mRNA Vaccine Immune Response, Accelerating Preclinical Evaluation
Wyss Institute USA Overview Researchers at the Wyss Institute have developed an innovative technology capable of replicating mRNA vaccine-induced immune responses on patient-specific Lymphoid Organ Chips. This human-derived, ex vivo mode... -
RNA Medicines Enter ‘Second Act’ Post-COVID-19, Focusing on Extrahepatic Delivery Beyond the Liver
European Biotechnology Magazine Germany Overview RNA therapeutics are entering a 'second act' after the success of mRNA vaccines during the COVID-19 pandemic, with a critical focus on developing effective delivery technologies to extrahe... -
Cytokine Co-Presentation on Targeted Lipid Nanoparticles Enhances In Vivo T Cell Engineering: IL-7 Co-Presentation Biases Functional mRNA Transfection Towards Splenic T Cells
PubMed (bioRxiv) Unknown Overview This research describes an enhanced lipid nanoparticle (LNP) design that co-presents interleukin-7 (IL-7) with anti-CD3 and anti-CD28 antibodies. This novel LNP significantly improves particle uptake and... -
Oregon State University Develops Novel Sugar-Coated Nanoparticle Therapy for Glioblastoma: Boosting Mouse Survival by 50%
Oregon State University via Medical Xpress USA Overview Researchers at Oregon State University have developed a new experimental glioblastoma treatment using sugar-coated nanoparticles to deliver genetic instructions that restore a tumor... -
Nava Therapeutics Raises $89 Million for Lipid Nanoparticle (LNP) Platform: Innovating RNA Therapeutic Delivery
Endpoints News USA Overview Nava Therapeutics announced the completion of an $89 million Series A funding round to advance its lipid nanoparticle (LNP) platform, specialized in efficient RNA-based therapeutic delivery. This substantial f... -
Clarivate Releases ‘Drugs to Watch in 2026’ List: AI Drug Discovery and DDS Technologies Highlighted as Promising Candidates
Clarivate UK Overview Clarivate released its mid-year 'Drugs to Watch' list for 2026, emphasizing that AI drug discovery and innovative drug delivery system (DDS) technologies are key trends driving the future market. The list includes A... -
RNAi Therapeutics Advance in Metabolic Disease Treatment with Liver-Targeted DDS and Emerging Self-Delivery siRNAs
ResearchGate (Trends in Pharmacological Sciences) Unknown Overview This article discusses RNA interference (RNAi) as a therapeutic strategy for metabolic diseases, emphasizing its advantage in targeting virtually all genes. Despite deliv... -
Alloy Therapeutics Unveils AntiClastic™ Cyclic RNA Platform for Enhanced Potency and Reduced Off-Target Effects in Next-Gen RNA Medicines
Alloy Therapeutics USA Overview Alloy Therapeutics introduced its AntiClastic™ Cyclic Oligonucleotide platform, which reconfigures ASOs, siRNAs, and sgRNAs into proprietary cyclic architectures. This technology aims to enhance potency an...
